Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 29 APRIL 2022

Market Intelligence Thought Leadership Award Winner

The House Does It Again: MORE Act Ready For Senate Action

Sheppard
Sheppard
Contributor
Sheppard

Sheppard

Businesses turn to Sheppard to deliver sophisticated counsel to help clients move ahead. With more...

View firm profile
Explore more from Sheppard

Federal cannabis reform is once again on the move in Congress. On Friday, April 1, 2022, the U.S. House of Representatives passed the latest iteration of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act.

United StatesCannabis & Hemp
Jennifer N Le
Jennifer N Le
Author LinkedIn connections

Federal cannabis reform is once again on the move in Congress. On Friday, April 1, 2022, the U.S. House of Representatives passed the latest iteration of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act. This is Congress's oldest comprehensive measure, and it aims to decriminalize cannabis on the federal level by removing it from the list of controlled substances while providing certain social reforms to address the detrimental repercussions of the War on Drugs.1

Passing with a vote of 220-204, the MORE Act does not have overwhelming bipartisan support, with only 3 Republican representatives backing the bill. The MORE Act will face certain opposition in the Senate, especially if the past is any indication - the last time the House passed this bill, the Senate subsequently left it on the floor without calling for vote. Additionally, the Senate has its own comprehensive bill, the Cannabis Administrative and Opportunity ("CAO") Act, spearheaded by

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

See more popular content from

Article

The Intoxicating Hemp Products Ban Was Delayed A Month. Now What?

The House has passed a short-term funding bill postponing the federal ban on hemp-derived THC products from November 12th to December 11th. With comprehensive legislation unlikely before the new deadline and competing interests from cannabis sellers, alcohol producers, and state regulators creating policy gridlock, the future of intoxicating hemp products remains uncertain as midterm elections approach.
United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski
Article

IRC Section 280E And Cannabis Tax Planning: Recent Developments And Practical Considerations

The landscape surrounding Section 280E of the Internal Revenue Code continues to evolve with President Trump's Executive Order on medical marijuana rescheduling, advancing litigation in New Mexico Top Organics v. Commissioner, and shifting regulatory signals. Cannabis taxpayers face critical decisions about taking "non-280E" positions on their tax returns while the IRS maintains its enforcement stance and the U.S. Tax Court case addressing common arguments remains pending.
United StatesCannabis & Hemp
Foley Hoag LLP
Foley Hoag LLP
Article

"Marijuana" Rescheduling Delayed, Again. What It Could Mean, And What Comes Next

The DEA's marijuana rescheduling hearing has been unexpectedly stayed following a motion to admit a new GAO report examining agency scheduling procedures. With the proceeding on hold and the medical marijuana Schedule III order facing legal challenges in the D.C. Circuit, the cannabis industry's path to federal tax relief through rescheduling has become increasingly uncertain.
United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski
Article

FDA Balances Peptide Policy With Enforcement Against Unlawful Peptide Sellers

Over the past year, industry has had a front row seat as the Food and Drug Administration (“FDA” or the “Agency”) decides just how much leeway it wants to afford the manufacture, marketing, and sale of peptide products, and just where it wants to draw the line. Despite the recent decision of FDA’s Pharmacy Compounding Advisory Committee (“PCAC”) to recommend a number of peptides for inclusion on the 503A bulks list process — a move that represents a potentially more permissive stance toward peptide regulation, at least in terms of what can and cannot be compounded under 503A...
United StatesFood, Drugs, Healthcare, Life Sciences
Sheppard
Sheppard
Article

The Ninth Circuit Affirms Dismissal Of DMCA CMI Removal Claim Against AI Code Generator – Output Is A New Work Not A Copy Of Training Data

There was a significant ruling in the Doe v. Github case involving training of AI code generator models on open source. The United States Court of Appeals for The Ninth Circuit affirmed the district court ruling dismissing part of an action brought under the Digital Millennium Copyright Act (“DMCA”) by programmers against GitHub, Inc., and other defendants. The issues centered on whether defendants removed copyright management information (CMI) from content used to train the AI code generator models.
United StatesIntellectual Property
Sheppard
Sheppard
Article

Massachusetts Issues Guidance On Data Center Development Under Executive Order 658

Massachusetts Governor Maura Healey has issued Executive Order 658, establishing comprehensive permitting and regulatory standards for data centers exceeding 25 MW of peak electricity demand. The Order mandates community benefits agreements, clean energy procurement protocols, and coordination across multiple state agencies to ensure responsible development that protects ratepayers, communities, and the environment. This action positions Massachusetts alongside other states implementing stricter oversight o
United StatesEnergy and Natural Resources
Sheppard
Sheppard
Article

Fintech Agrees To Acquire National Bank Partner For $590 Million

A publicly traded fintech company has announced a $590 million acquisition of its longtime national bank partner, marking a strategic shift from the traditional bank-partnership model to direct ownership of a national bank charter. The transaction, expected to close in the first half of 2027 pending regulatory approvals, would make the fintech a bank holding company while consolidating its banking activities and eliminating certain sponsor-bank fees. This deal represents a faster alternative to pursuing a d
United StatesFinance and Banking
Sheppard
Sheppard